Search Results

Nicholas Holliday and how he has combined his university role with his leadership of Excellerate Bioscience

Industry News Inside the FDA's Form 483 findings at Novo Nordisk's North Carolina semaglutide plant Excellerate Bioscience Announces Site Relocation AI can help to speed up drug discovery — but only if we give it

January 2022 "The Neurocrine Biosciences story puts into words what makes the work and people at Neurocrine Biosciences so special.

Since 2019, Nick has combined his university role with the leadership of Excellerate Bioscience as Chief Excellerate is involved in several pre-clinical drug discovery projects for both GPCR and non-GPCR targets Nicholas Holliday on the web LinkedIn ORCID University of Nottingham Twitter Excellerate Bio Dr.

Scientific Officer and VP of Protein Engineering at Twist Biopharma, the biologics division of Twist Bioscience 01:53 The conversation begins 02:29 From MIT crystallography to leading Twist Biopharma 04:21 Twist Bioscience Aaron Sato from Twist Biopharma , a vertical within Twist Bioscience . During our time together, Aaron and I discussed how using Twist Bioscience’s proprietary technology to Aaron Sato on the web LinkedIn Twitter Google Scholar Twist Bioscience Twist Biopharma Dr.

When Sam Hoare and the CRF receptor team at Neurocrin Biosciences discovered that their lead compound postdoc at the National Institutes of Health studying Class B GPCRs, he spent fifteen years at Neurocrin Biosciences mentorship, and conversations with Nobel laureates 35:38 Into industry: the CRF receptor team at Neurocrin Biosciences Hoare was a pharmacology leader in the pharmaceutical industry for 15 years at Neurocrine Biosciences